Published in Neurology on July 12, 2005
Brain-computer interfaces: communication and restoration of movement in paralysis. J Physiol (2007) 2.80
Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener (2014) 1.19
Depression and quality of life in patients with amyotrophic lateral sclerosis. Dtsch Arztebl Int (2008) 1.13
Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00
What lies behind the wish to hasten death? A systematic review and meta-ethnography from the perspective of patients. PLoS One (2012) 0.99
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.94
Psychopathological features and suicidal ideation in amyotrophic lateral sclerosis patients. Neurol Sci (2010) 0.88
Euthanasia and physician-assisted suicide in amyotrophic lateral sclerosis: a prospective study. J Neurol (2014) 0.88
Attitudes Toward Assisted Suicide and Life-Prolonging Measures in Swiss ALS Patients and Their Caregivers. Front Psychol (2012) 0.83
Does desire for hastened death change in terminally ill cancer patients? Soc Sci Med (2014) 0.83
Exit strategies in ALS: an influence of depression or despair? Neurology (2005) 0.82
Medical and supportive care among people with ALS in the months before death or tracheostomy. J Pain Symptom Manage (2009) 0.79
The management of amyotrophic lateral sclerosis. J Neurol (2009) 0.79
Wish to die in end-stage ALS. Neurology (2007) 0.76
An International Consensus Definition of the Wish to Hasten Death and Its Related Factors. PLoS One (2016) 0.76
Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. NeuroRehabilitation (2015) 0.75
Physician-assisted suicide: a review of the literature concerning practical and clinical implications for UK doctors. BMC Fam Pract (2006) 0.75
Wish to die in end-stage ALS. Neurology (2006) 0.75
Assessment of the wish to hasten death in patients with advanced disease: A systematic review of measurement instruments. Palliat Med (2016) 0.75
Recognizing Psychological Diversity in People with End-Stage Amyotrophic Lateral Sclerosis. AMA J Ethics (2015) 0.75
Religion as a Risk Factor for Suicide Attempt and Suicide Ideation Among Depressed Patients. J Nerv Ment Dis (2016) 0.75
The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol (1974) 9.96
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci (1999) 9.95
The nature of suffering and the goals of medicine. N Engl J Med (1982) 7.08
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA (2004) 5.43
Euthanasia and physician-assisted suicide: attitudes and experiences of oncology patients, oncologists, and the public. Lancet (1996) 4.76
Physician reports of terminal sedation without hydration or nutrition for patients nearing death in the Netherlands. Ann Intern Med (2004) 4.66
Desire for death in the terminally ill. Am J Psychiatry (1995) 3.87
Dignity in the terminally ill: a cross-sectional, cohort study. Lancet (2002) 3.73
Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet (2003) 3.72
Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med (2002) 3.51
Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med (1998) 3.39
Are amyotrophic lateral sclerosis patients cognitively normal? Neurology (2003) 3.21
Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA (2000) 3.05
Nurses' experiences with hospice patients who refuse food and fluids to hasten death. N Engl J Med (2003) 2.89
Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA (2000) 2.62
Experiences of Oregon nurses and social workers with hospice patients who requested assistance with suicide. N Engl J Med (2002) 2.61
Interest in physician-assisted suicide among ambulatory HIV-infected patients. Am J Psychiatry (1996) 2.01
Characteristics and proportion of dying Oregonians who personally consider physician-assisted suicide. J Clin Ethics (2004) 1.85
Attitudes of terminally ill patients toward euthanasia and physician-assisted suicide. Arch Intern Med (2000) 1.68
The schedule of attitudes toward hastened death: Measuring desire for death in terminally ill cancer patients. Cancer (2000) 1.17
Characteristics of patients requesting and receiving physician-assisted death. Arch Intern Med (2003) 1.14
Factors associated with the wish to hasten death: a study of patients with terminal illness. Psychol Med (2003) 1.03
Disparities in perceptions of distress and burden in ALS patients and family caregivers. Neurology (2004) 1.03
The relationship of pain and symptom management to patient requests for physician-assisted suicide. J Pain Symptom Manage (1991) 1.00
Predictors and correlates of interest in assisted suicide in the final month of life among ALS patients in Oregon and Washington. J Pain Symptom Manage (2002) 0.99
Attitudes toward physician-assisted suicide among persons with multiple sclerosis. J Palliat Med (1999) 0.86
The existential moment. Palliat Support Care (2003) 0.84
Informal caregivers and the intention to hasten AIDS-related death. Arch Intern Med (1998) 0.83
Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol (1984) 5.21
Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology (1988) 4.28
Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology (2003) 3.82
Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell (1988) 3.57
Phase II/III randomized trial of TCH346 in patients with ALS. Neurology (2007) 3.22
Live events, stress, and illness. Science (1976) 3.05
Inclusion body myositis and myopathies. Ann Neurol (1995) 2.68
Primary lateral sclerosis. A clinical diagnosis reemerges. Arch Neurol (1988) 2.62
Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology (2009) 2.60
The natural history of primary lateral sclerosis. Neurology (2006) 2.31
Premorbid weight, body mass, and varsity athletics in ALS. Neurology (2002) 2.23
Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord (1992) 2.15
Neurolymphomatosis: a clinicopathologic syndrome re-emerges. Neurology (1992) 2.14
Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med (1997) 2.12
Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology (2004) 2.09
Heterogeneity of clinical response during placebo treatment. Am J Psychiatry (1991) 2.06
Complications of intravenous immune globulin treatment in neurologic disease. Neurology (1996) 1.97
Myoglobinuria. Med Clin North Am (1972) 1.95
Lumping or splitting? "Ophthalmoplegia-plus" or Kearns-Sayre syndrome? Ann Neurol (1977) 1.90
Adult Dental Health Survey 2009: transformations in British oral health 1968-2009. Br Dent J (2012) 1.90
Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol (2000) 1.82
Prevalence of depressive disorders and change over time in late-stage ALS. Neurology (2005) 1.80
A clinical trial of creatine in ALS. Neurology (2004) 1.73
Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell? N Engl J Med (1994) 1.73
Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med (1987) 1.72
A prospective study of preferences and actual treatment choices in ALS. Neurology (1999) 1.71
Cramps. N Engl J Med (1971) 1.67
Novel mutations in spastin gene and absence of correlation with age at onset of symptoms. Neurology (2000) 1.67
Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry (1984) 1.66
A randomized controlled trial of resistance exercise in individuals with ALS. Neurology (2007) 1.65
"Maximal" thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg (1988) 1.63
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology (2007) 1.63
Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology (1990) 1.61
Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol (1991) 1.60
Muscular dystrophy in young girls. Neurology (1970) 1.60
Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care (2000) 1.56
Lymphoproliferative disorders and motor neuron disease: an update. Neurology (1997) 1.54
Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med (1980) 1.54
Muscle phosphofructokinase deficiency. Arch Neurol (1967) 1.54
Polyglucosan body disease. Muscle Nerve (1991) 1.50
Two novel pathogenic mitochondrial DNA mutations affecting organelle number and protein synthesis. Is the tRNA(Leu(UUR)) gene an etiologic hot spot? J Clin Invest (1993) 1.48
Drugs, coma, and myoglobinuria. Arch Neurol (1972) 1.47
Adult Dental Health Survey 2009: relationships between dental attendance patterns, oral health behaviour and the current barriers to dental care. Br Dent J (2013) 1.47
Emery-Dreifuss muscular dystrophy. Ann Neurol (1979) 1.42
Physical therapy for a patient through six stages of amyotrophic lateral sclerosis. Phys Ther (1998) 1.42
The ALSFRSr predicts survival time in an ALS clinic population. Neurology (2005) 1.42
ALS defeats gabapentin: reflections on another failed treatment. Neurology (2001) 1.41
Different types of placebo response in patients receiving antidepressants. Am J Psychiatry (1991) 1.40
Ashkenazi-Jewish and non-Jewish adult GM2 gangliosidosis patients share a common genetic defect. Am J Hum Genet (1990) 1.40
A computerised log for the emergency department resuscitation room. Emerg Med J (2003) 1.39
Intermittent esotropia associated with rippling muscle disease. J Neuroophthalmol (1995) 1.38
Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology (1997) 1.36
Prognosis of ocular myasthenia. Ann Neurol (1983) 1.35
Biochemistry of muscle membranes in Duchenne muscular dystrophy. Muscle Nerve (1980) 1.34
Möbius syndrome and facioscapulohumeral muscular dystrophy. Arch Neurol (1971) 1.32
Medical and dental students' attitudes about the AIDS epidemic. Acad Med (1990) 1.32
Controversies about the treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry (1980) 1.30
Pathogenesis of muscular dystrophies. Arch Neurol (1976) 1.28
A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology (2006) 1.28
Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl (1993) 1.26
Dystrophinopathy in isolated cases of myopathy in females. Neurology (1992) 1.23
Cramps, spasms and muscle stiffness. Rev Neurol (Paris) (1985) 1.22
Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry (1994) 1.22
Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology (1994) 1.20
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology (1999) 1.20
Hypertension and DSM-III depression in psychiatric outpatients. Am J Psychiatry (1983) 1.20
Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Am J Drug Alcohol Abuse (1999) 1.20
Physical and kinetic properties of human phosphofructokinase from skeletal muscle and erythrocytes. J Biol Chem (1969) 1.19
Normal pressure hydrocephalus and hypertensive cerebrovascular disease. Arch Neurol (1974) 1.19
Diverse forms of motor neuron diseases. Adv Neurol (1982) 1.17
Hyperkalemic periodic paralysis. Arch Neurol (1967) 1.17
Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry (1991) 1.17
Motor neuron disease and adult hexosaminidase A deficiency in two families: evidence for multisystem degeneration. Ann Neurol (1985) 1.17
Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum (1987) 1.15
How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res (1986) 1.15
The relationship between employment and neuropsychological impairment in HIV infection. J Int Neuropsychol Soc (1999) 1.15
Validity of clinical trials of antidepressants. Am J Psychiatry (2000) 1.14
Juvenile spinal muscular atrophy: a new hexosaminidase deficiency phenotype. Ann Neurol (1982) 1.13
Hyperkalemic periodic paralysis and cardiac arrhythmia. Neurology (1972) 1.13
A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine palmityl transferase. N Engl J Med (1975) 1.11
Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology (2009) 1.11
Ethnic density and psychiatric hospitalization: hazards of minority status. Am J Psychiatry (1979) 1.10
Perineurioma as the cause of localized hypertrophic neuropathy. Muscle Nerve (1980) 1.10
Myasthenia as an autoimmune disease: clinical aspects. Ann N Y Acad Sci (1966) 1.09
Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull (1987) 1.08
Classification of neuromuscular disorders. J Neurol Sci (1994) 1.08